Marshall Wace, LLP Cardiff Oncology, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 143,026 shares of CRDF stock, worth $358,995. This represents 0.0% of its overall portfolio holdings.
Number of Shares
143,026
Previous 298,829
52.14%
Holding current value
$358,995
Previous $663,000
42.53%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CRDF
# of Institutions
90Shares Held
12.3MCall Options Held
813KPut Options Held
91.1K-
Black Rock Inc. New York, NY2.63MShares$6.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$5.45 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA928KShares$2.33 Million0.0% of portfolio
-
State Street Corp Boston, MA833KShares$2.09 Million0.0% of portfolio
-
Mai Capital Management663KShares$1.67 Million0.02% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $109M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...